Wall Street analysts predict that PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) will announce earnings per share of ($0.40) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for PhaseBio Pharmaceuticals’ earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.46). PhaseBio Pharmaceuticals posted earnings per share of ($0.26) in the same quarter last year, which indicates a negative year over year growth rate of 53.8%. The firm is expected to report its next earnings results on Tuesday, March 24th.
On average, analysts expect that PhaseBio Pharmaceuticals will report full year earnings of ($1.39) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($1.21). For the next fiscal year, analysts expect that the firm will post earnings of ($1.79) per share, with EPS estimates ranging from ($2.15) to ($1.57). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow PhaseBio Pharmaceuticals.
PhaseBio Pharmaceuticals (NASDAQ:PHAS) last posted its quarterly earnings results on Thursday, November 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.35 million. PhaseBio Pharmaceuticals had a negative return on equity of 53.00% and a negative net margin of 1,768.29%.
A number of institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio purchased a new position in shares of PhaseBio Pharmaceuticals during the 2nd quarter valued at $48,000. JPMorgan Chase & Co. purchased a new position in PhaseBio Pharmaceuticals in the second quarter worth $48,000. TD Asset Management Inc. grew its position in PhaseBio Pharmaceuticals by 26.9% in the second quarter. TD Asset Management Inc. now owns 40,343 shares of the company’s stock worth $529,000 after acquiring an additional 8,555 shares in the last quarter. United Services Automobile Association grew its position in PhaseBio Pharmaceuticals by 15.8% in the second quarter. United Services Automobile Association now owns 107,267 shares of the company’s stock worth $1,407,000 after acquiring an additional 14,653 shares in the last quarter. Finally, Wells Fargo & Company MN purchased a new position in PhaseBio Pharmaceuticals in the second quarter worth $211,000. Institutional investors and hedge funds own 66.33% of the company’s stock.
NASDAQ:PHAS opened at $3.39 on Friday. The company has a current ratio of 13.98, a quick ratio of 16.52 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $96.37 million and a PE ratio of -0.76. The firm’s 50 day moving average is $4.00 and its 200 day moving average is $8.08. PhaseBio Pharmaceuticals has a 12 month low of $2.56 and a 12 month high of $16.65.
About PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.
Read More: What is the definition of arbitrage?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.